Nalaganje...
Nivolumab induced myxedema crisis
BACKGROUND: Nivolumab is an anti-programmed cell death (anti-PD-1) monoclonal antibody that is approved by Food and Drug Administration for treatment of metastatic non-small cell lung cancer, metastatic melanoma, relapsed Hodgkin lymphoma and advanced renal cell cancer. We report a rare case of myxe...
Shranjeno v:
| izdano v: | J Immunother Cancer |
|---|---|
| Main Authors: | , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
BioMed Central
2017
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5319087/ https://ncbi.nlm.nih.gov/pubmed/28239466 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40425-017-0213-x |
| Oznake: |
Označite
Brez oznak, prvi označite!
|